KIT and neoplasm: In this regard, it is noted that the c-Kit inhibitor imatinib inhibited breast stromal fibroblasts and reduced tumor growth [40], and that c-Kit/CSF1R inhibitors target tumor-promoting M2 macrophages in the TME of solid tumors [41].